Prudent Man Advisors LLC Increases Stock Holdings in Becton, Dickinson and Company $BDX

Prudent Man Advisors LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,432 shares of the medical instruments supplier’s stock after acquiring an additional 965 shares during the quarter. Prudent Man Advisors LLC’s holdings in Becton, Dickinson and Company were worth $1,108,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in Becton, Dickinson and Company by 257.4% during the 2nd quarter. Brighton Jones LLC now owns 6,737 shares of the medical instruments supplier’s stock valued at $1,160,000 after acquiring an additional 4,852 shares during the period. Graybill Wealth Management LTD. boosted its stake in shares of Becton, Dickinson and Company by 1.5% in the 2nd quarter. Graybill Wealth Management LTD. now owns 18,733 shares of the medical instruments supplier’s stock valued at $3,227,000 after buying an additional 281 shares during the period. CVA Family Office LLC boosted its stake in shares of Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 97 shares during the period. AG2R LA Mondiale Gestion D Actifs boosted its stake in shares of Becton, Dickinson and Company by 8.3% in the 2nd quarter. AG2R LA Mondiale Gestion D Actifs now owns 12,105 shares of the medical instruments supplier’s stock valued at $2,085,000 after buying an additional 924 shares during the period. Finally, Focus Partners Advisor Solutions LLC boosted its stake in shares of Becton, Dickinson and Company by 42.3% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 4,500 shares of the medical instruments supplier’s stock valued at $775,000 after buying an additional 1,337 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.4%

Shares of BDX stock opened at $185.85 on Friday. The business’s fifty day moving average price is $189.93 and its 200 day moving average price is $183.97. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The firm has a market capitalization of $53.27 billion, a PE ratio of 33.43, a P/E/G ratio of 1.45 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion for the quarter. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BDX. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Morgan Stanley raised their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $205.40.

Insiders Place Their Bets

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 1,838 shares of company stock worth $348,392 over the last quarter. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.